Sarubbi F A, Hull J H
Ann Intern Med. 1978 Nov;89(5 Pt 1):612-8. doi: 10.7326/0003-4819-89-5-612.
Amikacin is a new aminoglycoside antibiotic that behaves pharmacokinetically similar to kanamycin, gentamicin, and tobramycin. Our study was designed to test whether a digital computer program could correctly predict amikacin serum concentrations in the clinical setting. A significant relation (P less than 0.0001) was found between 153 measured (bioassayed) and computer-predicted levels from 26 patients. The computer program reliably estimated amikacin serum levels after either intravenous or intramuscular doses. Prediction accuracy was not significantly affected by patient sex, hematocrit, or periods of unstable renal function. Predicted levels were most accurate when based on creatinine clearance corrected to 70 kg body weight or corrected to body surface area. The pharmacokinetic parameters in the computer program were used to generate a new aminoglycoside dosing chart. Ten patients were given amikacin according to this guideline, and the mean peak serum level for the group was 25.6 microgram/ml.
阿米卡星是一种新型氨基糖苷类抗生素,其药代动力学特性与卡那霉素、庆大霉素和妥布霉素相似。我们的研究旨在测试数字计算机程序能否在临床环境中正确预测阿米卡星的血清浓度。在26例患者的153次测量(生物测定)水平与计算机预测水平之间发现了显著相关性(P小于0.0001)。该计算机程序能够可靠地估计静脉或肌肉注射剂量后阿米卡星的血清水平。预测准确性不受患者性别、血细胞比容或肾功能不稳定期的显著影响。当根据校正至70kg体重或校正至体表面积的肌酐清除率进行预测时,预测水平最为准确。计算机程序中的药代动力学参数被用于生成新的氨基糖苷类给药图表。10例患者按照该指南使用阿米卡星,该组的平均血清峰值水平为25.6微克/毫升。